• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
PROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer's and Parkinson's Diseases.用于治疗神经退行性疾病（阿尔茨海默病和帕金森病）的靶向α-突触核蛋白的PROTAC化合物
ACS Med Chem Lett. 2020 Apr 28;11(6):1086-1087. doi: 10.1021/acsmedchemlett.0c00192. eCollection 2020 Jun 11.
2
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度：一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
3
Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases.天然多酚对阿尔茨海默病和帕金森病朊病毒样疾病中蛋白质聚集体的影响。
Neural Regen Res. 2018 Jun;13(6):955-961. doi: 10.4103/1673-5374.233432.
4
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.帕金森病和退行性痴呆症患者的脑脊液 Tau/α-突触核蛋白比值。
Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.
5
Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.帕金森病的诊断生物标志物：聚焦于脑脊液中的 α-突触核蛋白。
Parkinsonism Relat Disord. 2019 Feb;59:21-25. doi: 10.1016/j.parkreldis.2018.11.016. Epub 2018 Nov 15.
6
Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease.阿尔茨海默病合并脑路易体病中的心脏交感神经去神经支配和α-突触核蛋白病
Brain Commun. 2020;2(1):fcaa004. doi: 10.1093/braincomms/fcaa004. Epub 2020 Jan 28.
7
Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.寡聚化 alpha-突触核蛋白的膜相互作用：在帕金森病中的潜在作用。
Curr Protein Pept Sci. 2010 Aug;11(5):334-42. doi: 10.2174/138920310791330659.
8
Glycation in Parkinson's disease and Alzheimer's disease.帕金森病和阿尔茨海默病中的糖基化作用。
Mov Disord. 2016 Jun;31(6):782-90. doi: 10.1002/mds.26566. Epub 2016 Mar 4.
9
Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls.与阿尔茨海默病患者及对照组相比，帕金森病患者血清α-突触核蛋白自身抗体水平升高。
Front Neurol. 2017 Dec 22;8:720. doi: 10.3389/fneur.2017.00720. eCollection 2017.
10
Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.来自孔图尔西家族、帕金森病和阿尔茨海默病患者脑样本中的新型α-突触核蛋白免疫反应性蛋白。
Exp Neurol. 1998 Dec;154(2):684-90. doi: 10.1006/exnr.1998.6975.

引用本文的文献

1
Targeted degradation of α-synuclein by arginine-based PROTACs.基于精氨酸的PROTACs对α-突触核蛋白的靶向降解
J Biol Chem. 2025 Jul 2;301(8):110449. doi: 10.1016/j.jbc.2025.110449.
2
Amyloid-reoriented enzyme catalysis.淀粉样蛋白重定向酶催化
Nat Commun. 2025 Apr 2;16(1):3164. doi: 10.1038/s41467-025-58536-5.
3
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation.用于淀粉样变性的蛋白水解治疗方法：对免疫疗法、PROTAC和光氧化的见解。
Neurotherapeutics. 2025 Apr;22(3):e00548. doi: 10.1016/j.neurot.2025.e00548. Epub 2025 Feb 11.
4
Advancements in PROTAC-based therapies for neurodegenerative diseases.基于PROTAC的神经退行性疾病治疗方法的进展。
Future Med Chem. 2025 Mar;17(5):591-605. doi: 10.1080/17568919.2025.2463310. Epub 2025 Feb 11.
5
Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics.α-突触核蛋白构象体的非直观免疫原性和可塑性：神经免疫疗法智能递送的范例
Pharmaceutics. 2024 Apr 30;16(5):609. doi: 10.3390/pharmaceutics16050609.
6
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?中枢神经系统疾病中的靶向蛋白质降解：通往新型疗法的一条有前景的途径？
Front Mol Neurosci. 2024 Apr 15;17:1370509. doi: 10.3389/fnmol.2024.1370509. eCollection 2024.
7
Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.破坏坏蛋白——降解剂的发现途径与走向临床。
Cells. 2024 Mar 26;13(7):578. doi: 10.3390/cells13070578.
8
Proximity-Induced Pharmacology for Amyloid-Related Diseases.淀粉样相关疾病的临近诱导药理学。
Cells. 2024 Mar 4;13(5):449. doi: 10.3390/cells13050449.
9
Perspective Strategies for Interventions in Parkinsonism: Remedying the Neglected Role of TPPP.帕金森病干预策略的视角：纠正 TPPP 被忽视的作用。
Cells. 2024 Feb 14;13(4):338. doi: 10.3390/cells13040338.
10
Role of NFE2L1 in the Regulation of Proteostasis: Implications for Aging and Neurodegenerative Diseases.NFE2L1在蛋白质稳态调节中的作用：对衰老和神经退行性疾病的影响
Biology (Basel). 2023 Aug 25;12(9):1169. doi: 10.3390/biology12091169.

本文引用的文献

1
Immunotherapies in Huntington's disease and α-Synucleinopathies.免疫疗法在亨廷顿病和 α-突触核蛋白病中的应用。
Front Immunol. 2020 Feb 25;11:337. doi: 10.3389/fimmu.2020.00337. eCollection 2020.
2
Immunotherapy for Parkinson's disease.帕金森病的免疫疗法。
Neurobiol Dis. 2020 Apr;137:104760. doi: 10.1016/j.nbd.2020.104760. Epub 2020 Jan 21.
3
Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.以α-突触核蛋白为靶点治疗帕金森病
Front Mol Neurosci. 2019 Dec 5;12:299. doi: 10.3389/fnmol.2019.00299. eCollection 2019.
4
New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.针对帕金森病中 alpha-synuclein 的新治疗方法：免疫疗法的作用。
Int Rev Neurobiol. 2019;146:281-295. doi: 10.1016/bs.irn.2019.06.014. Epub 2019 Jul 18.
5
Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.靶向帕金森病中的α-突触核蛋白：开发疾病修饰治疗方法的进展。
Drugs. 2019 Jun;79(8):797-810. doi: 10.1007/s40265-019-01104-1.

PROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer's and Parkinson's Diseases.

作者信息

Kargbo Robert B

机构信息

Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.

出版信息

ACS Med Chem Lett. 2020 Apr 28;11(6):1086-1087. doi: 10.1021/acsmedchemlett.0c00192. eCollection 2020 Jun 11.

DOI:10.1021/acsmedchemlett.0c00192
PMID:32550983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7294559/
Abstract
摘要